(Reuters) - Medicines Company, a maker of drugs used in hospitals, will spend about $300 million in two deals to bulk up its surgical care products portfolio. The company will pay $105 million upfront for a two-year license to market Bristol-Myers Squibb Company's device to control bleeding during surgery. Medicines Co also said it agreed to pay $185 million to acquire privately held Incline Therapeutics, which is developing a device to manage post-operative pain. "Both assets fit well with Medicines Co's current hospital franchise. ... Click here to read the rest
No comments:
Post a Comment